Studies on serum YKL-40 as a biomarker in diseases with inflammation, tissue remodeling, fibrosis and cancer:
Gespeichert in:
| 1. Verfasser: | |
|---|---|
| Format: | Buch |
| Sprache: | English |
| Veröffentlicht: |
København
Laegeforeningens Forl.
2006
|
| Schlagworte: | |
| Online-Zugang: | Inhaltsverzeichnis |
| Beschreibung: | Zsfassung in dän. Sprache. - Zugl.: København, Univ., Diss., 2006 |
| Beschreibung: | 67 S. graph. Darst. |
| ISBN: | 8778911281 |
Internformat
MARC
| LEADER | 00000nam a2200000 c 4500 | ||
|---|---|---|---|
| 001 | BV021638312 | ||
| 003 | DE-604 | ||
| 005 | 20070703 | ||
| 007 | t | ||
| 008 | 060630s2006 d||| m||| 00||| eng d | ||
| 020 | |a 8778911281 |9 87-7891-128-1 | ||
| 035 | |a (OCoLC)634229936 | ||
| 035 | |a (DE-599)BVBBV021638312 | ||
| 040 | |a DE-604 |b ger |e rakwb | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-29 | ||
| 100 | 1 | |a Johansen, Julia S. |e Verfasser |4 aut | |
| 245 | 1 | 0 | |a Studies on serum YKL-40 as a biomarker in diseases with inflammation, tissue remodeling, fibrosis and cancer |c Julia S. Johansen |
| 264 | 1 | |a København |b Laegeforeningens Forl. |c 2006 | |
| 300 | |a 67 S. |b graph. Darst. | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b n |2 rdamedia | ||
| 338 | |b nc |2 rdacarrier | ||
| 500 | |a Zsfassung in dän. Sprache. - Zugl.: København, Univ., Diss., 2006 | ||
| 650 | 0 | 7 | |a Glykoproteine |0 (DE-588)4071905-4 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Biomarker |0 (DE-588)4425928-1 |2 gnd |9 rswk-swf |
| 655 | 7 | |0 (DE-588)4113937-9 |a Hochschulschrift |2 gnd-content | |
| 689 | 0 | 0 | |a Glykoproteine |0 (DE-588)4071905-4 |D s |
| 689 | 0 | 1 | |a Biomarker |0 (DE-588)4425928-1 |D s |
| 689 | 0 | |5 DE-604 | |
| 856 | 4 | 2 | |m HBZ Datenaustausch |q application/pdf |u http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=014853135&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |3 Inhaltsverzeichnis |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-014853135 | ||
Datensatz im Suchindex
| _version_ | 1804135439115747328 |
|---|---|
| adam_text | Contents
1. YKL 40 9
YKL 40 amino acid and cDNA sequence 9
YKL 40 gene 9
YKL 40 structure 10
YKL 40 expression in non malignant cells 10
Macrophages 10
Neutrophil granulocytes 11
Chondrocytes 11
Fibroblast like synovial cells (synoviocytes) .. 12
Bone cells 12
Vascular smooth muscle cells 12
Liver cells 12
Mammary epithelial cells 12
Malignant cells 12
Other cells/tissues 12
Biologic activities of YKL 40 13
Growth properties 13
Heparin binding properties 14
Chitin binding properties 14
Effect on hyaluronan synthesis 15
Regulation of YKL 40 15
Effect of different extracellular matrix (ECM) 15
Effect of cytokines and growth factors 16
Conclusions and future perspectives 16
2. Aim 17
3. Methods for determination of YKL 40
in tissues and body fluids 17
Microarray cDNA analysis 17
In situ hybridization 17
Immunohistochemical analysis 17
Radio and enzyme linked immunoassays for the
determination of YKL 40 17
Serum/plasma concentrations of YKL 40 in
healthy subjects IS
Individual variation in serum YKL 40
concentrations 19
Stability of YKL 40 concentrations in blood
after venipuncture 19
Conclusions and future perspectives 20
4. YKL 40 in non malignant diseases
characterized by inflammation, remodeling
of the extracellular matrix or development
of fibrosis 20
4.1. Infectious diseases 20
Conclusions and future perspectives 23
4.2. Joint diseases 23
Rheumatoid arthritis 23
YKL 40 in relation to etiology of RA 23
YKL 40 expression in synovial membrane
and cartilage of RA patients 24
Biomarkers of disease activity and prognosis
in RA 25
Synovial fluid concentrations of YKL 40
in RA patients 27
Serum YKL 40 concentrations in RA patients
in relation to disease activity 27
Serum YKL 40 concentrations in RA patients
during different treatment regimens 30
Serum YKL 40 concentrations in RA patients
in relation to radiographic joint damage ... 32
Osteoarthritis 33
YKL 40 expression in cartilage and synovial
membrane of OA patients 33
Synovial fluid and serum concentrations
of YKL 40 in OA patients 34
Ankylosing spondylitis 35
Conclusions and future perspectives 35
4.3. Diseases with chronic inflammation and
granuhma formation 36
Giant cell arteritis 36
Inflammatory bowel disease 37
Sarcoidosis 3X
Systemic sclerosis 39
Heart transplantation 39
Conclusions and future perspectives 39
4.4. Liver fibrosis 40
YKL 40 expression in the liver 41
Serum concentrations of YKL 40 in patients
with liver disease in relation to liver fibrosis,
disease activity and prognosis 41
Conclusions and future perspectives 42
5
5. YKL 40 in cancer diseases 43
Is serum YKL 40 a new biomarker in
cancer patients? 44
The marker is produced exclusively by
specific tumor cells (tumor specific)? 45
The marker is absent in healthy or benign
disease (high specificity)? 45
The marker is present frequently in the
targeted malignancy (high sensitivity)? ... 45
The marker is detectable in early stage
subclinical disease (useful for screening)? . 47
The marker s concentration reflects prognosis
for an individual patient (prognosticator)? 47
The marker s degree of expression correlates
with therapeutic results (useful for
monitoring)? 49
YKL 40 and liver metastases 49
Conclusions and future perspectives 49
6
6. General conclusions 50
7. Danish summary 52
8. References 53
|
| adam_txt |
Contents
1. YKL 40 9
YKL 40 amino acid and cDNA sequence 9
YKL 40 gene 9
YKL 40 structure 10
YKL 40 expression in non malignant cells 10
Macrophages 10
Neutrophil granulocytes 11
Chondrocytes 11
Fibroblast like synovial cells (synoviocytes) . 12
Bone cells 12
Vascular smooth muscle cells 12
Liver cells 12
Mammary epithelial cells 12
Malignant cells 12
Other cells/tissues 12
Biologic activities of YKL 40 13
Growth properties 13
Heparin binding properties 14
Chitin binding properties 14
Effect on hyaluronan synthesis 15
Regulation of YKL 40 15
Effect of different extracellular matrix (ECM) 15
Effect of cytokines and growth factors 16
Conclusions and future perspectives 16
2. Aim 17
3. Methods for determination of YKL 40
in tissues and body fluids 17
Microarray cDNA analysis 17
In situ hybridization 17
Immunohistochemical analysis 17
Radio and enzyme linked immunoassays for the
determination of YKL 40 17
Serum/plasma concentrations of YKL 40 in
healthy subjects IS
Individual variation in serum YKL 40
concentrations 19
Stability of YKL 40 concentrations in blood
after venipuncture 19
Conclusions and future perspectives 20
4. YKL 40 in non malignant diseases
characterized by inflammation, remodeling
of the extracellular matrix or development
of fibrosis 20
4.1. Infectious diseases 20
Conclusions and future perspectives 23
4.2. Joint diseases 23
Rheumatoid arthritis 23
YKL 40 in relation to etiology of RA 23
YKL 40 expression in synovial membrane
and cartilage of RA patients 24
Biomarkers of disease activity and prognosis
in RA 25
Synovial fluid concentrations of YKL 40
in RA patients 27
Serum YKL 40 concentrations in RA patients
in relation to disease activity 27
Serum YKL 40 concentrations in RA patients
during different treatment regimens 30
Serum YKL 40 concentrations in RA patients
in relation to radiographic joint damage . 32
Osteoarthritis 33
YKL 40 expression in cartilage and synovial
membrane of OA patients 33
Synovial fluid and serum concentrations
of YKL 40 in OA patients 34
Ankylosing spondylitis 35
Conclusions and future perspectives 35
4.3. Diseases with chronic inflammation and
granuhma formation 36
Giant cell arteritis 36
Inflammatory bowel disease 37
Sarcoidosis 3X
Systemic sclerosis 39
Heart transplantation 39
Conclusions and future perspectives 39
4.4. Liver fibrosis 40
YKL 40 expression in the liver 41
Serum concentrations of YKL 40 in patients
with liver disease in relation to liver fibrosis,
disease activity and prognosis 41
Conclusions and future perspectives 42
5
5. YKL 40 in cancer diseases 43
Is serum YKL 40 a new biomarker in
cancer patients? 44
The marker is produced exclusively by
specific tumor cells (tumor specific)? 45
The marker is absent in healthy or benign
disease (high specificity)? 45
The marker is present frequently in the
targeted malignancy (high sensitivity)? . 45
The marker is detectable in early stage
subclinical disease (useful for screening)? . 47
The marker's concentration reflects prognosis
for an individual patient (prognosticator)? 47
The marker's degree of expression correlates
with therapeutic results (useful for
monitoring)? 49
YKL 40 and liver metastases 49
Conclusions and future perspectives 49
6
6. General conclusions 50
7. Danish summary 52
8. References 53 |
| any_adam_object | 1 |
| any_adam_object_boolean | 1 |
| author | Johansen, Julia S. |
| author_facet | Johansen, Julia S. |
| author_role | aut |
| author_sort | Johansen, Julia S. |
| author_variant | j s j js jsj |
| building | Verbundindex |
| bvnumber | BV021638312 |
| ctrlnum | (OCoLC)634229936 (DE-599)BVBBV021638312 |
| format | Book |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01430nam a2200349 c 4500</leader><controlfield tag="001">BV021638312</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">20070703 </controlfield><controlfield tag="007">t</controlfield><controlfield tag="008">060630s2006 d||| m||| 00||| eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">8778911281</subfield><subfield code="9">87-7891-128-1</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)634229936</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV021638312</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-29</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Johansen, Julia S.</subfield><subfield code="e">Verfasser</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Studies on serum YKL-40 as a biomarker in diseases with inflammation, tissue remodeling, fibrosis and cancer</subfield><subfield code="c">Julia S. Johansen</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">København</subfield><subfield code="b">Laegeforeningens Forl.</subfield><subfield code="c">2006</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">67 S.</subfield><subfield code="b">graph. Darst.</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">Zsfassung in dän. Sprache. - Zugl.: København, Univ., Diss., 2006</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Glykoproteine</subfield><subfield code="0">(DE-588)4071905-4</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Biomarker</subfield><subfield code="0">(DE-588)4425928-1</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="655" ind1=" " ind2="7"><subfield code="0">(DE-588)4113937-9</subfield><subfield code="a">Hochschulschrift</subfield><subfield code="2">gnd-content</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Glykoproteine</subfield><subfield code="0">(DE-588)4071905-4</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="1"><subfield code="a">Biomarker</subfield><subfield code="0">(DE-588)4425928-1</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">HBZ Datenaustausch</subfield><subfield code="q">application/pdf</subfield><subfield code="u">http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=014853135&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-014853135</subfield></datafield></record></collection> |
| genre | (DE-588)4113937-9 Hochschulschrift gnd-content |
| genre_facet | Hochschulschrift |
| id | DE-604.BV021638312 |
| illustrated | Illustrated |
| index_date | 2024-07-02T14:59:11Z |
| indexdate | 2024-07-09T20:40:31Z |
| institution | BVB |
| isbn | 8778911281 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-014853135 |
| oclc_num | 634229936 |
| open_access_boolean | |
| owner | DE-29 |
| owner_facet | DE-29 |
| physical | 67 S. graph. Darst. |
| publishDate | 2006 |
| publishDateSearch | 2006 |
| publishDateSort | 2006 |
| publisher | Laegeforeningens Forl. |
| record_format | marc |
| spelling | Johansen, Julia S. Verfasser aut Studies on serum YKL-40 as a biomarker in diseases with inflammation, tissue remodeling, fibrosis and cancer Julia S. Johansen København Laegeforeningens Forl. 2006 67 S. graph. Darst. txt rdacontent n rdamedia nc rdacarrier Zsfassung in dän. Sprache. - Zugl.: København, Univ., Diss., 2006 Glykoproteine (DE-588)4071905-4 gnd rswk-swf Biomarker (DE-588)4425928-1 gnd rswk-swf (DE-588)4113937-9 Hochschulschrift gnd-content Glykoproteine (DE-588)4071905-4 s Biomarker (DE-588)4425928-1 s DE-604 HBZ Datenaustausch application/pdf http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=014853135&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA Inhaltsverzeichnis |
| spellingShingle | Johansen, Julia S. Studies on serum YKL-40 as a biomarker in diseases with inflammation, tissue remodeling, fibrosis and cancer Glykoproteine (DE-588)4071905-4 gnd Biomarker (DE-588)4425928-1 gnd |
| subject_GND | (DE-588)4071905-4 (DE-588)4425928-1 (DE-588)4113937-9 |
| title | Studies on serum YKL-40 as a biomarker in diseases with inflammation, tissue remodeling, fibrosis and cancer |
| title_auth | Studies on serum YKL-40 as a biomarker in diseases with inflammation, tissue remodeling, fibrosis and cancer |
| title_exact_search | Studies on serum YKL-40 as a biomarker in diseases with inflammation, tissue remodeling, fibrosis and cancer |
| title_exact_search_txtP | Studies on serum YKL-40 as a biomarker in diseases with inflammation, tissue remodeling, fibrosis and cancer |
| title_full | Studies on serum YKL-40 as a biomarker in diseases with inflammation, tissue remodeling, fibrosis and cancer Julia S. Johansen |
| title_fullStr | Studies on serum YKL-40 as a biomarker in diseases with inflammation, tissue remodeling, fibrosis and cancer Julia S. Johansen |
| title_full_unstemmed | Studies on serum YKL-40 as a biomarker in diseases with inflammation, tissue remodeling, fibrosis and cancer Julia S. Johansen |
| title_short | Studies on serum YKL-40 as a biomarker in diseases with inflammation, tissue remodeling, fibrosis and cancer |
| title_sort | studies on serum ykl 40 as a biomarker in diseases with inflammation tissue remodeling fibrosis and cancer |
| topic | Glykoproteine (DE-588)4071905-4 gnd Biomarker (DE-588)4425928-1 gnd |
| topic_facet | Glykoproteine Biomarker Hochschulschrift |
| url | http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=014853135&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |
| work_keys_str_mv | AT johansenjulias studiesonserumykl40asabiomarkerindiseaseswithinflammationtissueremodelingfibrosisandcancer |